RESUMO
Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed.
Assuntos
Hepatite A , Hepatite B , Humanos , Estudos Retrospectivos , Hepatite B/tratamento farmacológico , Hepatite B/epidemiologia , Hepatite B/prevenção & controle , Vírus da Hepatite B , Terapia de Imunossupressão/efeitos adversos , Infecção Persistente , Antivirais/uso terapêuticoRESUMO
Cytokine storms can be triggered by various infectious or noninfectious diseases and cause severe damages to multiple organs. Cytokine storm plays an important role in the pathogenesis of severe cases of coronavirus disease 2019 (COVID-19). The pathogenesis of COVID-19 involves a potent inflammatory response involving a complex group of mediators, including interleukin (IL)-6 and IL-10. In this study, the serum levels of IL-6 and IL-10 cytokines were evaluated in 79 COVID-19 infected patients from the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt. And 20 healthy individuals served as a control group. The patients were divided into moderate, severe, and critically ill. In this study, IL-6 and IL-10 levels were significantly elevated in COVID-19 patients compared with healthy controls. IL-6 levels were significantly higher in patients compared with controls (p = 0.001), although it was not varied within different severity groups except for moderate-critical ill cases (p < 0.033). IL-10 only showed a significant difference between critically ill and control cases (p < 0.002). Receiver operating characteristic curve analyses showed that IL-6 levels >120 pg/mL can predict moderate and critically ill patients with a sensitivity of 90.48% and a specificity of 62.50%, Area Under the Curve <0.0001. In conclusion, the serum levels of IL-6 cytokine are important noninvasive biomarkers to differentiate between moderate and critically ill COVID-19 infected patients.
RESUMO
BACKGROUND & AIMS: Patients with thalassemia have a lifelong need for blood transfusion, which makes them more risky to hepatitis C virus (HCV). Iron overload and chronic HCV are considered risk factors for patients with thalassemia to develop liver insults. The aim of the present study is to investigate the safety and efficacy of sofosbuvir/ledipasvir in the treatment of chronic HCV infection in Egyptian adult patients with ß- thalassemia major. METHODS: A retrospective study included 53 patients with ß-thalassemia major with chronic HCV treated with sofosbuvir (400 mg) and ledipasvir (90 mg) as a single pill fixed-dose combination once daily for 12 weeks. The effectiveness of the treatment was assessed by the sustained virologic response (SVR) at 12 weeks after the end of the treatment. RESULTS: SVR was achieved in 96.23% of patients. 47.17% of patients had minor side effects. There was a significant reduction in ALT, AST, and serum ferritin 12 weeks post-therapy. There was an insignificant change in hemoglobin level or blood transfusion requirement 12 weeks posttherapy. There was no change in iron chelators doses throughout the study period. CONCLUSION: Sofosbuvir/ledipasvir regimen seems to be safe and highly effective in the treatment of chronic HCV in patients with ß-thalassemia major.